These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 27175600)

  • 1. Met and its ligand HGF are associated with clinical outcome in breast cancer.
    Veenstra C; Pérez-Tenorio G; Stelling A; Karlsson E; Mirwani SM; Nordensköljd B; Fornander T; Stål O
    Oncotarget; 2016 Jun; 7(24):37145-37159. PubMed ID: 27175600
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased MET and HGF gene copy numbers are associated with trastuzumab failure in HER2-positive metastatic breast cancer.
    Minuti G; Cappuzzo F; Duchnowska R; Jassem J; Fabi A; O'Brien T; Mendoza AD; Landi L; Biernat W; Czartoryska-Arłukowicz B; Jankowski T; Zuziak D; Zok J; Szostakiewicz B; Foszczyńska-Kłoda M; Tempińska-Szałach A; Rossi E; Varella-Garcia M
    Br J Cancer; 2012 Aug; 107(5):793-9. PubMed ID: 22850551
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Frequent hepatocyte growth factor overexpression and low frequency of c-Met gene amplification in human papillomavirus-negative tonsillar squamous cell carcinoma and their prognostic significances.
    Kwon MJ; Kim DH; Park HR; Shin HS; Kwon JH; Lee DJ; Kim JH; Cho SJ; Nam ES
    Hum Pathol; 2014 Jul; 45(7):1327-38. PubMed ID: 24810547
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of HGF, pMet, and pAkt is related to benefit of radiotherapy after breast-conserving surgery: a long-term follow-up of the SweBCG91-RT randomised trial.
    Sjöström M; Veenstra C; Holmberg E; Karlsson P; Killander F; Malmström P; Niméus E; Fernö M; Stål O
    Mol Oncol; 2020 Nov; 14(11):2713-2726. PubMed ID: 32946618
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changes in PlGF and MET-HGF expressions in paired initial and recurrent glioblastoma.
    Tabouret E; Denicolai E; Delfino C; Graillon T; Boucard C; Nanni I; Padovani L; Figarella-Branger D; Chinot O
    J Neurooncol; 2016 Dec; 130(3):431-437. PubMed ID: 27566180
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comprehensive molecular analyses of lung adenocarcinoma with regard to the epidermal growth factor receptor, K-ras, MET, and hepatocyte growth factor status.
    Onitsuka T; Uramoto H; Ono K; Takenoyama M; Hanagiri T; Oyama T; Izumi H; Kohno K; Yasumoto K
    J Thorac Oncol; 2010 May; 5(5):591-6. PubMed ID: 20150826
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MET and phosphorylated MET as potential biomarkers in lung cancer.
    Tretiakova M; Salama AK; Karrison T; Ferguson MK; Husain AN; Vokes EE; Salgia R
    J Environ Pathol Toxicol Oncol; 2011; 30(4):341-54. PubMed ID: 22181983
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased gene copy number of HER2 and concordant protein overexpression found in a subset of eyelid sebaceous gland carcinoma indicate HER2 as a potential therapeutic target.
    Lee MJ; Kim N; Choung HK; Choe JY; Khwarg SI; Kim JE
    J Cancer Res Clin Oncol; 2016 Jan; 142(1):125-33. PubMed ID: 26141290
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential expression of c-Met, its ligand HGF/SF and HER2/neu in DCIS and adjacent normal breast tissue.
    Lindemann K; Resau J; Nährig J; Kort E; Leeser B; Annecke K; Welk A; Schäfer J; Vande Woude GF; Lengyel E; Harbeck N
    Histopathology; 2007 Jul; 51(1):54-62. PubMed ID: 17593080
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatocyte growth factor/scatter factor expression and c-met in primary breast cancer.
    Nagy J; Curry GW; Hillan KJ; McKay IC; Mallon E; Purushotham AD; George WD
    Surg Oncol; 1996 Feb; 5(1):15-21. PubMed ID: 8837300
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic and expression analysis of MET, MACC1, and HGF in metastatic colorectal cancer: response to met inhibition in patient xenografts and pathologic correlations.
    Galimi F; Torti D; Sassi F; Isella C; Corà D; Gastaldi S; Ribero D; Muratore A; Massucco P; Siatis D; Paraluppi G; Gonella F; Maione F; Pisacane A; David E; Torchio B; Risio M; Salizzoni M; Capussotti L; Perera T; Medico E; Di Renzo MF; Comoglio PM; Trusolino L; Bertotti A
    Clin Cancer Res; 2011 May; 17(10):3146-56. PubMed ID: 21447729
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Co-expression of hepatocyte growth factor and c-Met predicts peritoneal dissemination established by autocrine hepatocyte growth factor/c-Met signaling in gastric cancer.
    Toiyama Y; Yasuda H; Saigusa S; Matushita K; Fujikawa H; Tanaka K; Mohri Y; Inoue Y; Goel A; Kusunoki M
    Int J Cancer; 2012 Jun; 130(12):2912-21. PubMed ID: 21796631
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of the hepatocyte growth factor/c-Met pathway is increased at the cancer front in breast carcinoma.
    Edakuni G; Sasatomi E; Satoh T; Tokunaga O; Miyazaki K
    Pathol Int; 2001 Mar; 51(3):172-8. PubMed ID: 11328532
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cooperative Effect of Oncogenic
    Liu S; Li S; Wang B; Liu W; Gagea M; Chen H; Sohn J; Parinyanitikul N; Primeau T; Do KA; Vande Woude GF; Mendelsohn J; Ueno NT; Mills GB; Tripathy D; Gonzalez-Angulo AM
    Mol Cancer Ther; 2019 Feb; 18(2):399-412. PubMed ID: 30518672
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Up-regulation of hepatocyte growth factor receptor: an amplification and targeting mechanism for hepatocyte growth factor action in acute renal failure.
    Liu Y; Tolbert EM; Lin L; Thursby MA; Sun AM; Nakamura T; Dworkin LD
    Kidney Int; 1999 Feb; 55(2):442-53. PubMed ID: 9987069
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Concurrent MET copy number gain and KRAS mutation is a poor prognostic factor in pancreatobiliary subtype ampullary cancers.
    Kwon MJ; Kim JW; Jeon JY; Nam ES; Cho SJ; Park HR; Min SK; Seo J; Min KW; Choe JY; Lee HK
    Pathol Res Pract; 2017 Apr; 213(4):381-388. PubMed ID: 28214200
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatocyte growth factor expression in EGFR mutant lung cancer with intrinsic and acquired resistance to tyrosine kinase inhibitors in a Japanese cohort.
    Yano S; Yamada T; Takeuchi S; Tachibana K; Minami Y; Yatabe Y; Mitsudomi T; Tanaka H; Kimura T; Kudoh S; Nokihara H; Ohe Y; Yokota J; Uramoto H; Yasumoto K; Kiura K; Higashiyama M; Oda M; Saito H; Yoshida J; Kondoh K; Noguchi M
    J Thorac Oncol; 2011 Dec; 6(12):2011-7. PubMed ID: 22052230
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical significance of hepatocyte growth factor/c-Met expression in the assessment of gastric cancer progression.
    Noguchi E; Saito N; Kobayashi M; Kameoka S
    Mol Med Rep; 2015 May; 11(5):3423-31. PubMed ID: 25592281
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The HGF inhibitory peptide HGP-1 displays promising in vitro and in vivo efficacy for targeted cancer therapy.
    Chen L; Li C; Zhu Y
    Oncotarget; 2015 Oct; 6(30):30088-101. PubMed ID: 26254225
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activation of the hepatocyte growth factor (HGF)-Met system in papillary thyroid cancer: biological effects of HGF in thyroid cancer cells depend on Met expression levels.
    Mineo R; Costantino A; Frasca F; Sciacca L; Russo S; Vigneri R; Belfiore A
    Endocrinology; 2004 Sep; 145(9):4355-65. PubMed ID: 15192042
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.